← Back to Search

Behavioral Intervention

Contingency Management for Cannabis Use in HIV

N/A
Recruiting
Led By Chukwuemeka N Okafor, PhD, MPH
Research Sponsored by The University of Texas Health Science Center at San Antonio
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
Diagnosed or receiving treatment for a current major depressive or anxiety disorder
Diagnosed with any current alcohol or substance use disorder (excluding nicotine) using the Structured Clinical Interview for Clinical Disorders (SCID) Interview (22)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28-days
Awards & highlights
No Placebo-Only Group

Summary

This trial will test the feasibility and impact of 28 days of abstinence from cannabis use on symptoms of depression and anxiety, pain, sleep, cannabis use withdrawal, HIV viral load and biomarkers of systemic inflammation among people with HIV who use cannabis regularly.

Who is the study for?
This trial is for people living with HIV who use cannabis at least weekly, can speak English, and are willing to try not using cannabis for 28 days while attending study visits. They must have a positive urine test for cannabis but cannot be seeking treatment for its use or have any major substance abuse disorders (except nicotine), psychiatric conditions, or other issues that could make the trial unsafe.
What is being tested?
The study tests if giving money as motivation helps participants stop using cannabis for 28 days. It looks at how quitting affects their depression, anxiety, pain, sleep quality, withdrawal symptoms from stopping cannabis use, HIV viral load levels and inflammation markers in the body.
What are the potential side effects?
Since this trial involves abstaining from cannabis rather than taking new medications, it does not list specific side effects like drug trials do. However, participants might experience withdrawal symptoms such as irritability or difficulty sleeping.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am currently diagnosed with or being treated for depression or anxiety.
Select...
I do not have a current alcohol or substance use disorder.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28-days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 28-days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Sustained cannabis abstinence for 28-days

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Contingency Management - CannabisExperimental Treatment1 Intervention
Participants will be incentivized following biochemical verification (from urine samples) of cannabis abstinence.

Find a Location

Who is running the clinical trial?

The University of Texas Health Science Center at San AntonioLead Sponsor
476 Previous Clinical Trials
92,865 Total Patients Enrolled
The University of Texas Health Sciences Center, HoustonUNKNOWN
National Institute on Drug Abuse (NIDA)NIH
2,606 Previous Clinical Trials
3,329,824 Total Patients Enrolled
Baylor UniversityLead Sponsor
62 Previous Clinical Trials
66,015 Total Patients Enrolled
Chukwuemeka N Okafor, PhD, MPHPrincipal InvestigatorThe University of Texas Health Science Center at San Antonio

Media Library

Contingency Management - Cannabis (Behavioral Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT04866004 — N/A
Human Immunodeficiency Virus Infection Research Study Groups: Contingency Management - Cannabis
Contingency Management - Cannabis (Behavioral Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04866004 — N/A
Human Immunodeficiency Virus Infection Clinical Trial 2023: Contingency Management - Cannabis Highlights & Side Effects. Trial Name: NCT04866004 — N/A
Human Immunodeficiency Virus Infection Patient Testimony for trial: Trial Name: NCT04866004 — N/A
~10 spots leftby Dec 2025